Clinical trial
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With…
NCT00281931 · German CLL Study Group, Other · Terminated
Key facts
| NCT number | NCT00281931 |
|---|---|
| Title | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia |
| Official title | Phase II Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients With B-PLL |
| Lead sponsor | German CLL Study Group, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prolymphocytic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide, fludarabine phosphate |
| Enrollment | 21 |
| Start date | Sep 1, 1999 |
| Primary completion | Apr 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Jan 25, 2006 |
| Last update posted | Sep 26, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: